Insider Transactions Reported by 14 Insiders of Ovid Therapeutics Inc.

Symbol
OVID on Nasdaq
Location
New York, NY

Insiders trading volume in the past year

Ovid Therapeutics Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
TAKEDA PHARMACEUTICAL CO LTD 10%+ Owner $11,680,054 08 Dec 2025
Jeremy M. Levin Director $5,584,763 26 Feb 2026
Amit Rakhit PoA President and CMO $1,562,669 14 Jul 2021
Jeffrey A. Rona Cbfo $237,595 -$12,384 -5% 23 Feb 2026
Stelios Papadopoulos Director $112,000 26 Feb 2026
Margaret A. Alexander President and CEO, Director $89,537 -$16,901 -16% 23 Feb 2026
Jason Tardio Chief Operating Officer $60,469 22 Feb 2024
Thomas M. Perone Poa General Counsel, Secretary $60,469 22 Feb 2024
Kevin Joseph Fitzgerald Director 26 Feb 2026
Robert Michael Poole Poa Director 22 Feb 2024
Douglas E. Williams Director 17 May 2021
Bart Friedman Director 26 Feb 2026
Karen Bernstein Director 26 Feb 2026
Barbara Gayle Duncan Director 26 Feb 2026

Recent Insider Transactions by Companies or Individuals for Ovid Therapeutics Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Margaret A. Alexander OVID Employee Stock Option (Right to Buy) Award 1,435,000 1,435,000 26 Feb 2026 Direct
Stelios Papadopoulos OVID Employee Stock Option (Right to Buy) Award 65,000 65,000 26 Feb 2026 Direct
Kevin Joseph Fitzgerald OVID Employee Stock Option (Right to Buy) Award 65,000 65,000 26 Feb 2026 Direct
Jeremy M. Levin OVID Employee Stock Option (Right to Buy) Award 957,000 957,000 26 Feb 2026 Direct
Bart Friedman OVID Employee Stock Option (Right to Buy) Award 65,000 65,000 26 Feb 2026 Direct
Barbara Gayle Duncan OVID Employee Stock Option (Right to Buy) Award 65,000 65,000 26 Feb 2026 Direct
Karen Bernstein OVID Employee Stock Option (Right to Buy) Award 65,000 65,000 26 Feb 2026 Direct
Jeffrey A. Rona OVID Common Stock Award 77.2% 68,125 156,313 26 Feb 2026 Direct
Jeffrey A. Rona OVID Employee Stock Option (Right to Buy) Award 408,750 408,750 26 Feb 2026 Direct
Margaret A. Alexander OVID Common Stock Sale -15.9% $16,901 $1.45 -11,656 61,750 23 Feb 2026 Direct
Jeffrey A. Rona OVID Common Stock Sale -8.83% $12,384 $1.45 -8,541 88,188 23 Feb 2026 Direct
Margaret A. Alexander OVID Employee Stock Option (right to buy) Award 890,000 890,000 04 Jan 2026 Direct
Jeremy M. Levin OVID Common Stock Conversion of derivative security 1.96% 71,000 3,687,715 15 Dec 2025 Direct
Jeremy M. Levin OVID Series B Convertible Preferred Stock Conversion of derivative security -100% -71 0 15 Dec 2025 Direct
Jeremy M. Levin OVID Series B Warrant (right to buy) Purchase 35,500 35,500 11 Dec 2025 Direct
Jeremy M. Levin OVID Series A Warrant (right to buy) Purchase 47,333 47,333 11 Dec 2025 Direct
Jeremy M. Levin OVID Series B Convertible Preferred Stock Purchase 71 71 11 Dec 2025 Direct
Takeda Pharmaceutical Co Ltd OVID Common Stock Conversion of derivative security 21.7% 1,250,000 7,000,000 08 Dec 2025 See Explanation of Responses
Takeda Pharmaceutical Co Ltd OVID Series A Convertible Preferred Stock Conversion of derivative security -100% -1,250 0 08 Dec 2025 See Explanation of Responses
* An asterisk sign (*) next to the price indicates that the price is likely invalid.